HONG KONG – South Korea's Samyang Biopharmaceutical Corp. is set to expand to the U.S. with a new office in Boston, scheduled to open this month. The new location will focus on biologics product development as well as leveraging the local network for M&A opportunities.
HONG KONG – Sinovant Sciences Ltd., of Shanghai, has joined hands with U.S. firm Renexxion LLC to develop naronapride, an investigational gastrointestinal prokinetic for treating irritable bowel syndrome with constipation (IBS-C).
HONG KONG – Japan's Sanbio Co. Ltd., a maker of regenerative medicines for neurological disorders, is working with Keio University School of Medicine to research its SB-623 drug for the treatment of dementia, including Alzheimer's disease and cerebral vascular dementia.
HONG KONG – Sinovant Sciences Ltd., of Shanghai, has joined hands with U.S. firm Renexxion LLC to develop naronapride, an investigational gastrointestinal prokinetic for treating irritable bowel syndrome with constipation (IBS-C).
HONG KONG – Japan's Sanbio Co. Ltd., a maker of regenerative medicines for neurological disorders, is working with Keio University School of Medicine to research its SB-623 drug for the treatment of dementia, including Alzheimer's disease and cerebral vascular dementia.
HONG KONG – Changchun Changsheng Life Sciences Ltd., China's second largest rabies vaccine producer, was ordered to stop production and recall batches of its rabies vaccines after the China National Drug Administration (CNDA) reportedly uncovered falsified data and inspection records.
HONG KONG – In the wake of a canceled anti-monopoly probe, Chinese drugmaker Hainan Haiyao Co. Ltd. plans to acquire Haikou Qili Pharmacy Co. Ltd. for ¥2.142 billion (US$322 million).
HONG KONG – In the wake of a canceled anti-monopoly probe, Chinese drugmaker Hainan Haiyao Co. Ltd. plans to acquire Haikou Qili Pharmacy Co. Ltd. for ¥2.142 billion (US$322 million).
HONG KONG – Changchun Changsheng Life Sciences Ltd., China's second largest rabies vaccine producer, was ordered to stop production and recall batches of its rabies vaccines after the China National Drug Administration (CNDA) reportedly uncovered falsified data and inspection records.
